ET
CRSP icon

Entropy Technologies’s CRISPR Therapeutics CRSP Stock Holding History

Entropy Technologies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$612K Sell
11,220
-2,847
-20% -$150K 0.02% 620
2026
Q1 		$669K Buy
+14,067
New +$742K 0.03% 527
2025
Q3 		– Sell
-21,696
Closed -$1.06M – 868
2025
Q2 		$1.06M Buy
+21,696
New +$840K 0.08% 295
2024
Q4 		– Sell
-7,905
Closed -$371K – 780
2024
Q3 		$371K Sell
7,905
-7,497
-49% -$380K 0.04% 512
2024
Q2 		$832K Sell
15,402
-9,878
-39% -$571K 0.09% 275
2024
Q1 		$1.72M Buy
+25,280
New +$1.81M 0.18% 162

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Entropy Technologies's CRSP Position: Q2 2026 in Review

Entropy Technologies reduced its CRISPR Therapeutics (CRSP) stake by 20% in Q2 2026, selling an estimated $150K and leaving 11,220 shares worth $612K. The position accounts for 0.02% of the portfolio, ranked #620.

Entropy Technologies first reported a position in CRSP in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.72M in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Entropy Technologies held 11,220 shares of CRISPR Therapeutics worth $612K as of Q2 2026.
  • Entropy Technologies sold 2,847 CRISPR Therapeutics shares in Q2 2026, an estimated $150K.
  • CRISPR Therapeutics made up 0.02% of Entropy Technologies's portfolio in Q2 2026, its #620 holding.
  • Entropy Technologies first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Entropy Technologies's CRISPR Therapeutics position peaked at $1.72M in Q1 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.